Compare AbCellera Biologics Inc (ABCL) vs ArcelorMittal SA (MT) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

ArcelorMittal (MT) trades at $63.15, down 0.39% on the day, with a bullish technical signal supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.11 and P/S of 0.81. Recent news highlights expansion initiatives, a share buyback program, and a strategic AI collaboration with AWS to drive efficiency and lower-carbon steel production.

The outlook for MT is positive, driven by operational expansions and favorable steel import policies in Europe and the US, though risks include high capital expenditures and exposure to Chinese market weakness. Analyst sentiment is predominantly bullish with 50% buy ratings, supporting potential upside if earnings growth continues.